SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Cash from Financing Activities data on file, last reported at $89.9 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 51783.26% year-over-year to $89.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.4 million (up 27236.78% YoY) and the FY2025 annual result came in at $168.3 million, up 14452.36% from the prior year.
• Cash from Financing Activities climbed to $89.9 million in Q1 2026, from -$41685.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $168.7 million in Q3 2025 to a low of -$6.3 million in Q1 2022.
• A 5-year average of $19.1 million and a median of -$173985.0 in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 13794.46% — and 2026, when it jumped 51783.26%.
• Tracing SABS's Cash from Financing Activities over 5 years: stood at $8.4 million in 2022, then jumped by 706.4% to $67.6 million in 2023, then tumbled by 99.68% to $216961.0 in 2024, then slumped by 119.21% to -$41685.0 in 2025, then soared by 215815.78% to $89.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $89.9 million (Q1 2026), -$41685.0 (Q4 2025), and $168.7 million (Q3 2025), per Business Quant data.